First NCFB patient dosed in Phase IIa study of RESP-X
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives…
Infex invites you to Alderley Park's 10th Anniversary SciTech Extravaganza
Saturday 14 September, 10:00am - 3:00pm Come and join us in Glasshouse at…
Infex to present RESP-X Phase I data at ERS Congress
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives…
Infex strengthens its senior leadership team
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives…
Infex welcomes the UK government’s new five-year plan to combat antimicrobial resistance
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives…
Infex to present webinar on broader pipeline and growth strategy
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives…
Webinar on Infex's Phase II lead respiratory drug, RESP-X
On Jan 31st, Infex Therapeutics held a live webinar, to update on progress with…
Infex to present webinar on lead Phase II respiratory drug RESP-X
RESP-X is a potential blockbuster anti-virulence antibody drug to reduce the…
RESP-X successfully completes Phase I trial and initiates Phase IIa trial in NCFB patients
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives…
Approval for dosing final RESP-X Phase Ia cohort and first-in-patient Phase IIa
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives…